Intensity Therapeutics Inc
1 day chart
Kickstart your portfolio with a U.S. stock on us
Sign up and fund a new Wall St account and get a full share randomly chosen between GoPro, Dropbox or Nike.
Sign up and fund a new Wall St account and get a full U.S. share.
T&Cs apply
About INTS
Intensity Therapeutics, Inc. is a late-stage clinical biotechnology company. It is engaged in developing treatments that address both the regional and systemic nature of a patient’s cancer. Its platform creates patented anti-cancer product candidates comprising active anti-cancer agents and amphiphilic molecules. Its lead product candidate, INT230-6, comprises three components: cisplatin, a proven anti-cancer cytotoxic agent, vinblastine sulfate, also a proven anti-cancer cytotoxic agent, and an amphiphilic molecule (SHAO) which enables the two cytotoxic agents to disperse through a tumor and diffuse into cancer cells following a direct intratumoral injection. Its pipeline consists of INVINCIBLE-3 Study, a Phase 3 open-label, randomized study testing the superiority INT230-6 used as monotherapy compared to the standard of care drugs in 2nd and 3rd line treatment for certain soft tissue sarcoma subtypes, a Phase 2 clinical study in metastatic triple negative breast cancer.
Find out what a historical investment in Intensity Therapeutics Inc would be worth today using our INTS stock calculator.
$28.23M
-
0.00%
7.04M
$0.60
$0.42
$0.60
$3.17
$0.19
Ready to start your investing journey with Stake?
Open an accountINTS FAQs
- Sign up with some I.D. and zero paperwork
- Add funds to your account
- Make your first investment in INTS
This is not financial product advice nor a recommendation to invest in the securities listed. Past performance is not a reliable indicator of future performance. As always, do your own research and consider seeking financial, legal and taxation advice before investing. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.
Invest in INTS
on Stake
Buy INTS from US$3 brokerage
Invest in 9,500+ U.S. stocks and ETFs
Own a slice of INTS from only US$10 with fractional shares
